
Charanjit Aulakh
Examiner (ID: 8339, Phone: (571)272-0678 , Office: P/1625 )
| Most Active Art Unit | 1625 |
| Art Unit(s) | 1203, 1625, 1612, 1621 |
| Total Applications | 3782 |
| Issued Applications | 2867 |
| Pending Applications | 378 |
| Abandoned Applications | 586 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18565776
[patent_doc_number] => 20230256103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => CANNABINOID CONJUGATE MOLECULES
[patent_app_type] => utility
[patent_app_number] => 18/137760
[patent_app_country] => US
[patent_app_date] => 2023-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6201
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18137760
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/137760 | CANNABINOID CONJUGATE MOLECULES | Apr 20, 2023 | Pending |
Array
(
[id] => 20129138
[patent_doc_number] => 12371440
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-29
[patent_title] => Organic electro-optic chromophores
[patent_app_type] => utility
[patent_app_number] => 18/304764
[patent_app_country] => US
[patent_app_date] => 2023-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 13
[patent_no_of_words] => 4935
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 10
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18304764
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/304764 | Organic electro-optic chromophores | Apr 20, 2023 | Issued |
Array
(
[id] => 18565777
[patent_doc_number] => 20230256104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-17
[patent_title] => CANNABINOID CONJUGATE MOLECULES
[patent_app_type] => utility
[patent_app_number] => 18/137766
[patent_app_country] => US
[patent_app_date] => 2023-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6203
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 32
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18137766
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/137766 | Cannabinoid conjugate molecules | Apr 20, 2023 | Issued |
Array
(
[id] => 19049227
[patent_doc_number] => 20240091196
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 18/303267
[patent_app_country] => US
[patent_app_date] => 2023-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7917
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18303267
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/303267 | USE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE(III)] FOR THE TREATMENT OF CANCER | Apr 18, 2023 | Pending |
Array
(
[id] => 19096326
[patent_doc_number] => 20240115553
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-11
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY
[patent_app_type] => utility
[patent_app_number] => 18/135225
[patent_app_country] => US
[patent_app_date] => 2023-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31375
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18135225
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/135225 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Apr 16, 2023 | Abandoned |
Array
(
[id] => 18582848
[patent_doc_number] => 20230265103
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-24
[patent_title] => NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME
[patent_app_type] => utility
[patent_app_number] => 18/299657
[patent_app_country] => US
[patent_app_date] => 2023-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57578
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 1493
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18299657
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/299657 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | Apr 11, 2023 | Pending |
Array
(
[id] => 18683853
[patent_doc_number] => 11779563
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-10
[patent_title] => Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders
[patent_app_type] => utility
[patent_app_number] => 18/297973
[patent_app_country] => US
[patent_app_date] => 2023-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 23181
[patent_no_of_claims] => 40
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 322
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18297973
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/297973 | Oral cannabinoid pharmaceutical compositions and methods of treating sleep disorders | Apr 9, 2023 | Issued |
Array
(
[id] => 19930295
[patent_doc_number] => 12303488
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-05-20
[patent_title] => Cannabis based therapeutic and method of use
[patent_app_type] => utility
[patent_app_number] => 18/131052
[patent_app_country] => US
[patent_app_date] => 2023-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 24396
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 109
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18131052
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/131052 | Cannabis based therapeutic and method of use | Apr 4, 2023 | Issued |
Array
(
[id] => 18921311
[patent_doc_number] => 20240024315
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-25
[patent_title] => CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITOR AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID INHIBITOR FOR USE IN THE TREATMENT OR PREVENTION OF CARDIOVASCULAR DISEASES
[patent_app_type] => utility
[patent_app_number] => 18/130178
[patent_app_country] => US
[patent_app_date] => 2023-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6962
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18130178
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/130178 | Cholesteryl ester transfer protein (CETP) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases | Apr 2, 2023 | Issued |
Array
(
[id] => 18656128
[patent_doc_number] => 20230302005
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-28
[patent_title] => ACTIVE PHARMACEUTICAL INGREDIENT, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
[patent_app_type] => utility
[patent_app_number] => 18/126157
[patent_app_country] => US
[patent_app_date] => 2023-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19710
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18126157
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/126157 | ACTIVE PHARMACEUTICAL INGREDIENT, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | Mar 23, 2023 | Pending |
Array
(
[id] => 18647725
[patent_doc_number] => 20230293495
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES MEDIATED BY KDM1A
[patent_app_type] => utility
[patent_app_number] => 18/188578
[patent_app_country] => US
[patent_app_date] => 2023-03-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15786
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18188578
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/188578 | PHARMACEUTICAL FORMULATIONS FOR TREATING DISEASES MEDIATED BY KDM1A | Mar 22, 2023 | Pending |
Array
(
[id] => 18497275
[patent_doc_number] => 20230219887
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => SOLID FORMS COMPRISING AN OXIME ETHER COMPOUND, COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/185555
[patent_app_country] => US
[patent_app_date] => 2023-03-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27326
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18185555
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/185555 | SOLID FORMS COMPRISING AN OXIME ETHER COMPOUND, COMPOSITIONS AND METHODS OF USE THEREOF | Mar 16, 2023 | Abandoned |
Array
(
[id] => 18707508
[patent_doc_number] => 20230330084
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
[patent_app_type] => utility
[patent_app_number] => 18/121694
[patent_app_country] => US
[patent_app_date] => 2023-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52200
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18121694
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/121694 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | Mar 14, 2023 | Issued |
Array
(
[id] => 18964109
[patent_doc_number] => 11897859
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-02-13
[patent_title] => Coumarin compounds as antibacterial agents
[patent_app_type] => utility
[patent_app_number] => 18/119751
[patent_app_country] => US
[patent_app_date] => 2023-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8928
[patent_no_of_claims] => 11
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18119751
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/119751 | Coumarin compounds as antibacterial agents | Mar 8, 2023 | Issued |
Array
(
[id] => 18509945
[patent_doc_number] => 20230226037
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-20
[patent_title] => PROLONGED ECTOPARASITE-CONTROLLING AGENT FOR ANIMAL
[patent_app_type] => utility
[patent_app_number] => 18/119564
[patent_app_country] => US
[patent_app_date] => 2023-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33373
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18119564
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/119564 | Prolonged ectoparasite-controlling agent for animal | Mar 8, 2023 | Issued |
Array
(
[id] => 18466835
[patent_doc_number] => 20230201115
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-29
[patent_title] => CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 18/117328
[patent_app_country] => US
[patent_app_date] => 2023-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12198
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18117328
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/117328 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | Mar 2, 2023 | Pending |
Array
(
[id] => 18626608
[patent_doc_number] => 20230285402
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-14
[patent_title] => Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity
[patent_app_type] => utility
[patent_app_number] => 18/117257
[patent_app_country] => US
[patent_app_date] => 2023-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 58001
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18117257
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/117257 | Compositions and Methods of Modulating Short-Chain Dehydrogenase Activity | Mar 2, 2023 | Abandoned |
Array
(
[id] => 18707654
[patent_doc_number] => 20230330233
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS
[patent_app_type] => utility
[patent_app_number] => 18/116637
[patent_app_country] => US
[patent_app_date] => 2023-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5716
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18116637
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/116637 | COMPOSITIONS AND METHODS FOR DELIVERING PHARMACEUTICAL AGENTS | Mar 1, 2023 | Pending |
Array
(
[id] => 18483574
[patent_doc_number] => 20230210872
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-06
[patent_title] => TRYPTAMINE COMPOSITIONS FOR ENHANCING NEURITE OUTGROWTH
[patent_app_type] => utility
[patent_app_number] => 18/115966
[patent_app_country] => US
[patent_app_date] => 2023-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28941
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18115966
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/115966 | Tryptamine compositions for enhancing neurite outgrowth | Feb 28, 2023 | Issued |
Array
(
[id] => 19457803
[patent_doc_number] => 12098283
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-24
[patent_title] => Borate salts, polymers and composites
[patent_app_type] => utility
[patent_app_number] => 18/114055
[patent_app_country] => US
[patent_app_date] => 2023-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 7
[patent_no_of_words] => 8226
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18114055
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/114055 | Borate salts, polymers and composites | Feb 23, 2023 | Issued |